Annual EBIT
-$74.69 M
+$31.66 M+29.77%
December 31, 2023
Summary
- As of February 7, 2025, AUPH annual earnings before interest & taxes is -$74.69 million, with the most recent change of +$31.66 million (+29.77%) on December 31, 2023.
- During the last 3 years, AUPH annual EBIT has risen by +$29.60 million (+28.38%).
- AUPH annual EBIT is now -5688.89% below its all-time high of -$1.29 million, reached on November 30, 1999.
Performance
AUPH EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$16.02 M
+$13.34 M+498.47%
September 30, 2024
Summary
- As of February 7, 2025, AUPH quarterly earnings before interest & taxes is $16.02 million, with the most recent change of +$13.34 million (+498.47%) on September 30, 2024.
- Over the past year, AUPH quarterly EBIT has increased by +$13.34 million (+498.47%).
- AUPH quarterly EBIT is now at all-time high.
Performance
AUPH Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$15.14 M
+$27.76 M+64.71%
September 30, 2024
Summary
- As of February 7, 2025, AUPH TTM earnings before interest & taxes is -$15.14 million, with the most recent change of +$27.76 million (+64.71%) on September 30, 2024.
- Over the past year, AUPH TTM EBIT has increased by +$27.76 million (+64.71%).
- AUPH TTM EBIT is now -383.47% below its all-time high of $5.34 million, reached on March 31, 2012.
Performance
AUPH TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AUPH EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.8% | +498.5% | +64.7% |
| 3 y3 years | +28.4% | +299.3% | +86.7% |
| 5 y5 years | -33.6% | +299.3% | +86.7% |
AUPH EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.5% | at high | +142.3% | at high | +91.6% |
| 5 y | 5-year | at high | +58.5% | at high | +131.7% | at high | +91.6% |
| alltime | all time | -5688.9% | +58.5% | at high | +131.7% | -383.5% | +91.6% |
Aurinia Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.02 M(+498.5%) | -$15.14 M(-64.7%) |
| Jun 2024 | - | $2.68 M(-130.7%) | -$42.91 M(-25.6%) |
| Mar 2024 | - | -$8.73 M(-65.2%) | -$57.65 M(-22.8%) |
| Dec 2023 | -$74.69 M(-29.8%) | -$25.11 M(+113.7%) | -$74.69 M(-0.1%) |
| Sep 2023 | - | -$11.75 M(-2.7%) | -$74.78 M(+5.2%) |
| Jun 2023 | - | -$12.07 M(-53.2%) | -$71.06 M(-24.8%) |
| Mar 2023 | - | -$25.77 M(+2.3%) | -$94.50 M(-11.4%) |
| Dec 2022 | -$106.35 M(-41.0%) | -$25.19 M(+213.5%) | -$106.61 M(-6.1%) |
| Sep 2022 | - | -$8.04 M(-77.4%) | -$113.60 M(-27.1%) |
| Jun 2022 | - | -$35.51 M(-6.3%) | -$155.92 M(-6.9%) |
| Mar 2022 | - | -$37.88 M(+17.7%) | -$167.54 M(-7.0%) |
| Dec 2021 | -$180.21 M(+72.8%) | -$32.18 M(-36.1%) | -$180.21 M(+15.5%) |
| Sep 2021 | - | -$50.35 M(+6.8%) | -$156.08 M(+5.4%) |
| Jun 2021 | - | -$47.13 M(-6.7%) | -$148.04 M(+15.9%) |
| Mar 2021 | - | -$50.54 M(+527.7%) | -$127.77 M(+24.8%) |
| Dec 2020 | -$104.29 M(+14.7%) | -$8.05 M(-81.0%) | -$102.37 M(-25.8%) |
| Sep 2020 | - | -$42.31 M(+57.5%) | -$137.98 M(+20.3%) |
| Jun 2020 | - | -$26.86 M(+6.8%) | -$114.67 M(+10.6%) |
| Mar 2020 | - | -$25.14 M(-42.4%) | -$103.68 M(+14.0%) |
| Dec 2019 | -$90.94 M(+62.7%) | -$43.66 M(+129.8%) | -$90.94 M(+69.5%) |
| Sep 2019 | - | -$19.00 M(+19.7%) | -$53.66 M(+1.2%) |
| Jun 2019 | - | -$15.88 M(+28.0%) | -$53.00 M(+0.3%) |
| Mar 2019 | - | -$12.40 M(+94.5%) | -$52.83 M(-5.5%) |
| Dec 2018 | -$55.91 M(+18.8%) | -$6.38 M(-65.2%) | -$55.91 M(-9.3%) |
| Sep 2018 | - | -$18.34 M(+16.8%) | -$61.67 M(+8.0%) |
| Jun 2018 | - | -$15.71 M(+1.5%) | -$57.12 M(+11.0%) |
| Mar 2018 | - | -$15.48 M(+27.5%) | -$51.46 M(+9.3%) |
| Dec 2017 | -$47.06 M(+106.3%) | -$12.14 M(-12.0%) | -$47.06 M(+9.6%) |
| Sep 2017 | - | -$13.79 M(+37.2%) | -$42.95 M(+24.3%) |
| Jun 2017 | - | -$10.05 M(-9.3%) | -$34.55 M(+18.9%) |
| Mar 2017 | - | -$11.09 M(+38.1%) | -$29.05 M(+27.3%) |
| Dec 2016 | -$22.81 M(-3.2%) | -$8.03 M(+48.9%) | -$22.81 M(+12.3%) |
| Sep 2016 | - | -$5.39 M(+18.4%) | -$20.31 M(-4.9%) |
| Jun 2016 | - | -$4.55 M(-6.1%) | -$21.35 M(-6.6%) |
| Mar 2016 | - | -$4.85 M(-12.3%) | -$22.85 M(-3.1%) |
| Dec 2015 | -$23.58 M(+21.6%) | -$5.52 M(-14.1%) | -$23.58 M(-9.9%) |
| Sep 2015 | - | -$6.43 M(+6.2%) | -$26.16 M(+71.0%) |
| Jun 2015 | - | -$6.05 M(+8.5%) | -$15.29 M(-24.6%) |
| Mar 2015 | - | -$5.58 M(-31.2%) | -$20.28 M(+4.3%) |
| Dec 2014 | -$19.39 M(+199.7%) | -$8.11 M(-282.6%) | -$19.45 M(+49.5%) |
| Sep 2014 | - | $4.44 M(-140.2%) | -$13.01 M(-36.7%) |
| Jun 2014 | - | -$11.03 M(+132.5%) | -$20.54 M(+96.5%) |
| Mar 2014 | - | -$4.75 M(+184.5%) | -$10.45 M(+61.6%) |
| Dec 2013 | -$6.47 M(-33.2%) | -$1.67 M(-46.1%) | -$6.47 M(-34.9%) |
| Sep 2013 | - | -$3.10 M(+227.2%) | -$9.94 M(+16.3%) |
| Jun 2013 | - | -$946.00 K(+24.3%) | -$8.55 M(-13.7%) |
| Mar 2013 | - | -$761.00 K(-85.2%) | -$9.91 M(+3.2%) |
| Dec 2012 | -$9.68 M(+302.3%) | -$5.14 M(+202.1%) | -$9.60 M(+294.8%) |
| Sep 2012 | - | -$1.70 M(-26.1%) | -$2.43 M(+32.3%) |
| Jun 2012 | - | -$2.30 M(+408.3%) | -$1.84 M(-134.4%) |
| Mar 2012 | - | -$453.00 K(-122.4%) | $5.34 M(+33.5%) |
| Dec 2011 | -$2.41 M | $2.03 M(-282.9%) | $4.00 M(-985.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$1.11 M(-122.7%) | -$451.80 K(-39.4%) |
| Jun 2011 | - | $4.88 M(-372.1%) | -$745.00 K(-88.0%) |
| Mar 2011 | - | -$1.79 M(-26.2%) | -$6.22 M(+15.9%) |
| Dec 2010 | -$5.37 M(-28.5%) | -$2.43 M(+73.2%) | -$5.37 M(+120.4%) |
| Sep 2010 | - | -$1.40 M(+132.6%) | -$2.44 M(-18.5%) |
| Jun 2010 | - | -$602.40 K(-35.9%) | -$2.99 M(-39.2%) |
| Mar 2010 | - | -$939.80 K(-285.6%) | -$4.92 M(-27.5%) |
| Dec 2009 | -$7.51 M(-51.9%) | $506.40 K(-125.9%) | -$6.78 M(-22.4%) |
| Sep 2009 | - | -$1.95 M(-22.9%) | -$8.74 M(-17.2%) |
| Jun 2009 | - | -$2.53 M(-9.6%) | -$10.55 M(-22.4%) |
| Mar 2009 | - | -$2.80 M(+93.3%) | -$13.59 M(-14.9%) |
| Dec 2008 | -$15.62 M(-56.5%) | -$1.45 M(-61.5%) | -$15.97 M(-32.1%) |
| Sep 2008 | - | -$3.77 M(-32.4%) | -$23.51 M(-15.7%) |
| Jun 2008 | - | -$5.57 M(+7.4%) | -$27.90 M(-13.1%) |
| Mar 2008 | - | -$5.19 M(-42.3%) | -$32.09 M(-5.6%) |
| Dec 2007 | -$35.88 M(+48.6%) | -$8.98 M(+10.1%) | -$33.98 M(+9.2%) |
| Sep 2007 | - | -$8.16 M(-16.5%) | -$31.11 M(+5.0%) |
| Jun 2007 | - | -$9.76 M(+38.0%) | -$29.63 M(+13.7%) |
| Mar 2007 | - | -$7.08 M(+15.7%) | -$26.06 M(+9.2%) |
| Dec 2006 | -$24.15 M(-20.3%) | -$6.12 M(-8.4%) | -$23.87 M(-7.5%) |
| Sep 2006 | - | -$6.67 M(+7.8%) | -$25.81 M(-1.9%) |
| Jun 2006 | - | -$6.19 M(+26.7%) | -$26.30 M(-2.8%) |
| Mar 2006 | - | -$4.89 M(-39.3%) | -$27.07 M(-8.3%) |
| Dec 2005 | -$30.29 M(+30.8%) | -$8.06 M(+12.4%) | -$29.51 M(-2.2%) |
| Sep 2005 | - | -$7.17 M(+3.0%) | -$30.16 M(+1.7%) |
| Jun 2005 | - | -$6.96 M(-4.9%) | -$29.67 M(+11.1%) |
| Mar 2005 | - | -$7.32 M(-15.9%) | -$26.70 M(+17.2%) |
| Dec 2004 | -$23.16 M(+106.5%) | -$8.71 M(+30.5%) | -$22.79 M(+17.5%) |
| Sep 2004 | - | -$6.68 M(+67.3%) | -$19.39 M(+15.1%) |
| Jun 2004 | - | -$3.99 M(+17.1%) | -$16.85 M(+97.5%) |
| Mar 2004 | - | -$3.41 M(-35.8%) | -$8.53 M(+2.1%) |
| Dec 2003 | -$11.22 M(+627.0%) | -$5.31 M(+28.3%) | -$8.36 M(+36.1%) |
| Sep 2003 | - | -$4.14 M(-195.7%) | -$6.14 M(+2195.4%) |
| Jun 2003 | - | $4.33 M(-233.8%) | -$267.50 K(-88.4%) |
| Mar 2003 | - | -$3.24 M(+4.6%) | -$2.30 M(+61.1%) |
| Dec 2002 | -$1.54 M(-79.5%) | -$3.09 M(-278.4%) | -$1.43 M(-186.0%) |
| Sep 2002 | - | $1.73 M(-24.4%) | $1.66 M(-167.6%) |
| Jun 2002 | - | $2.29 M(-197.0%) | -$2.46 M(-69.3%) |
| Mar 2002 | - | -$2.36 M(-1.1%) | -$8.00 M(-24.0%) |
| Dec 2001 | -$7.53 M(+11.7%) | - | - |
| Aug 2001 | - | -$2.39 M(-26.6%) | -$10.53 M(+8.0%) |
| May 2001 | - | -$3.25 M(+42.9%) | -$9.76 M(+18.4%) |
| Feb 2001 | - | -$2.28 M(-13.0%) | -$8.24 M(+21.3%) |
| Nov 2000 | -$6.74 M(+422.4%) | -$2.62 M(+62.3%) | -$6.79 M(+41.6%) |
| Aug 2000 | - | -$1.61 M(-7.1%) | -$4.80 M(+47.5%) |
| May 2000 | - | -$1.74 M(+109.8%) | -$3.25 M(+69.1%) |
| Feb 2000 | - | -$827.00 K(+33.1%) | -$1.92 M(+48.5%) |
| Nov 1999 | -$1.29 M(-41.7%) | -$621.20 K(+828.6%) | -$1.29 M(+92.3%) |
| Aug 1999 | - | -$66.90 K(-83.6%) | -$672.70 K(+11.0%) |
| May 1999 | - | -$406.90 K(+104.6%) | -$605.80 K(+204.6%) |
| Feb 1999 | - | -$198.90 K | -$198.90 K |
| Nov 1998 | -$2.21 M | - | - |
FAQ
- What is Aurinia Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals annual EBIT year-on-year change?
- What is Aurinia Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals quarterly EBIT year-on-year change?
- What is Aurinia Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals TTM EBIT year-on-year change?
What is Aurinia Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of AUPH is -$74.69 M
What is the all time high annual EBIT for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high annual earnings before interest & taxes is -$1.29 M
What is Aurinia Pharmaceuticals annual EBIT year-on-year change?
Over the past year, AUPH annual earnings before interest & taxes has changed by +$31.66 M (+29.77%)
What is Aurinia Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of AUPH is $16.02 M
What is the all time high quarterly EBIT for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high quarterly earnings before interest & taxes is $16.02 M
What is Aurinia Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, AUPH quarterly earnings before interest & taxes has changed by +$13.34 M (+498.47%)
What is Aurinia Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of AUPH is -$15.14 M
What is the all time high TTM EBIT for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high TTM earnings before interest & taxes is $5.34 M
What is Aurinia Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, AUPH TTM earnings before interest & taxes has changed by +$27.76 M (+64.71%)